Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

This study has been completed.
Sponsor:
Collaborator:
Ortho Biotech Products, L.P.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00338299
First received: June 16, 2006
Last updated: May 19, 2011
Last verified: April 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2004
  Estimated Primary Completion Date: No date given